Cervomed Inc. (CRVO) Stock Price & Analysis
Cervomed Inc. (CRVO) fell 22.15% to USD 2.25 as of June 11, 2026 at 05:24 UTC, according to Nexqual real-time market data.
CRVO last closed at USD 2.89; the session ranged USD 2.15–2.74 on volume of 1,083,924 shares. Market capitalization is $20.83M, with a 52-week range of USD 2.15–13.13 (NCM). Source: Nexqual, June 11, 2026 at 05:24 UTC.
Key Statistics (as of June 11, 2026 at 05:24 UTC)
| Price | USD 2.25 |
|---|---|
| Change | ▼ 22.15% (down) |
| Previous Close | USD 2.89 |
| Open | USD 2.74 |
| Day Range | USD 2.15 – 2.74 |
| 52-Week Range | USD 2.15 – 13.13 |
| Volume | 1,083,924 shares |
| Market Cap | $20.83M |
| Exchange | NCM |
Technical Analysis (CRVO)
Nexqual's technical model rates CRVO "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 05:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.2 (neutral) |
| vs SMA50 | Below (USD 3.59) |
| MACD | -0.21 (negative) |
Analyst Ratings (CRVO)
Wall Street analysts rate CRVO "None" based on 6 analysts, with a mean price target of USD 20.33 (range USD 9–27), per Nexqual as of June 11, 2026 at 05:24 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 20.33 |
| High Target | USD 27 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (CRVO)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.79 |
| Revenue Estimate | $42,860 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.86 vs est -0.79 ▼ miss |
| 2025-12-31 | USD -0.88 vs est -0.7 ▼ miss |
| 2025-09-30 | USD -0.84 vs est -0.64 ▼ miss |
| 2025-06-30 | USD -0.7 vs est -0.62 ▼ miss |
Source: Nexqual, June 11, 2026 at 05:24 UTC.
Financials & Fundamentals (CRVO)
| Total Revenue | $2.09M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1488.86% |
| Profit Margin | +0.00% |
| ROE | -132.76% |
| Current Ratio | 3.36 |
| Total Cash | $12.92M |
| Total Debt | $0 |
| Free Cash Flow | $-16.30M |
Source: Nexqual, June 11, 2026 at 05:24 UTC.
Financial Health Score (CRVO)
Nexqual rates Cervomed Inc.'s overall financial health "Weak" across five dimensions, as of June 11, 2026 at 05:24 UTC.
| Growth | Critical — Revenue -59% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $13M cash, no debt |
| Cash Flow | Weak — FCF negative: -$16M, burning cash |
| Efficiency | Critical — ROE -133%, ROA -72.4% |
Ownership (CRVO)
| Insider Ownership | +32.84% |
|---|---|
| Institutional Ownership | +19.43% |
| Shares Outstanding | 9.26M |
| Float | 6.29M |
| Short % of Float | +4.13% |
Source: Nexqual, June 11, 2026 at 05:24 UTC.
Leadership (CRVO)
Cervomed Inc. is led by John J. Alam (age 63), Co-Founder, CEO, President & Director, per Nexqual as of June 11, 2026 at 05:24 UTC.
| Co-Founder, CEO, President & Director | John J. Alam (age 63) |
|---|---|
| Co-Founder & Director | Sylvie L. Gregoire Pharm.D. (age 64) |
| CFO, General Counsel & Corporate Secretary | William Robert Elder (age 42) |
| Executive Vice President of Clinical Development | Kelly Blackburn M.H.A. (age 61) |
| Executive Vice President of Technical Operations | Marinus Verwijs (age 49) |
Major Backers & Investors (CRVO)
Notable institutional backers of Cervomed Inc. include Morgan Stanley, Millennium Management, Renaissance Technologies, according to Nexqual as of June 11, 2026 at 05:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 7.99% |
| Millennium Management | 2.26% |
| Renaissance Technologies | 0.69% |
| Fidelity | 0.68% |
| Xtx Topco Ltd | 0.42% |
| Citizens Financial Group Inc/RI | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.22% |
| Geode Capital | 0.8% |
| BlackRock | 0.75% |
| Northern Trust | 0.32% |
Source: Nexqual, June 11, 2026 at 05:24 UTC.
From Cervomed Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
- The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
- Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
- Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DWTX | Dogwood Therapeutics, Inc. | USD 1.49 | ▲ 2.05% |
| PEPG | PepGen Inc. | USD 1.38 | ▲ 2.22% |
| TNON | Tenon Medical, Inc. | USD 0.6 | ▼ 0.57% |
| ALUR | Allurion Technologies Inc. | USD 0.83 | ▲ 12.16% |
| IBO | Impact BioMedical, Inc. | USD 0.57 | ▲ 1.61% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 05:24 UTC. This page is informational and not investment advice.